Renal Toxicity Presenting with a Fracture in an HIV Positive Adolescent

Abstract

Tenofovir is a nucleoside reverse transcriptase inhibitor commonly used to treat human immunodeficiency virus (HIV) infection in children and adolescents. We report a case of an HIV-positive adolescent male who had been treated with an antiretroviral regimen consisting of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) and lopinavir/ritonavir (LPV/r) with a stable CD4 count. Two and a half years after starting tenofovir, he experienced a right third metatarsal shaft fracture after minor trauma, which was treated successfully with a cast. He was found to have osteopenia for which he was treated with oral phosphate and calcium/vitamin D supplementation. Three months later, he then presented with severe hypokalemia, hypophosphatemia, normal anion gap metabolic acidosis, glycosuria, and proteinuria, which were consistent with a diagnosis of acquired Fanconi's syndrome. Subsequently, his electrolyte abnormalities were corrected with replacement of potassium, phosphate, and bicarbonate (Shohl's solution). His antiretroviral regimen was switched to abacavir/lamivudine and raltegravir. Acquired Fanconi's syndrome is a known but uncommon adverse effect of treatment with tenofovir, and an awareness that it can cause osteopenia and present with fractures can alert the physician to manage and prevent this potentially serious side effect.

Keywords

tenofovir - antiretroviral therapy - acquired Fanconi's syndrome - renal proximal tubulopathy - osteopenia

• References

• 1 HHS panel on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf . Accessed March 5, 2016
• 2 Waheed S, Attia D, Estrella MM. , et al. Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series. Clin Kidney J 2015; 8 (04) 420-425
• 3 Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57 (05) 773-780
• 4 Luni FK, Khan AR, Prashar R, Vetteth S, Duggan JM. Fanconi syndrome and antiretrovirals: it is never too late. Am J Ther 2016; 23 (02) e558-e560
• 5 Woodward CL, Hall AM, Williams IG. , et al. Tenofovir-associated renal and bone toxicity. HIV Med 2009; 10 (08) 482-487
• 6 Gupta SK, Anderson AM, Ebrahimi R. , et al. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS One 2014; 9 (03) e92717
• 7 Gallant JE, Daar ES, Raffi F. , et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV 2016; 3 (04) e158-e165
• 8 Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res 2016; 125: 63-70